Effective July 1, 2025, this agreement ensures that nearly 400,000 patients covered by IBX each year will keep receiving quality care from Penn Medicine providers. The partnership focuses on improving ...
The drug has shown strong results in phase 3 clinical trials, which are the basis for the new application to the FDA.
The FDA has accepted a new drug application for aficamten, a new obstructive hypertrophic cardiomyopathy drug. A goal date ...
Vitamin D receptor has antiproliferative effects in pulmonary arterial hypertension, but receptor expression is downregulated ...
A new nationwide study led by the Keck School of Medicine of USC aims to examine how type 1 diabetes impacts children's brain ...
ICER to Assess Sanofi’s Tolebrutinib for Secondary Progressive MS ...
Yesintek is the latest Stelara biosimilar to gain FDA approval and it will be available in February 2025.
If granted, Tremfya will be approved to treat children ages six and under with severe plaque psoriasis and children ages five ...
Seemal Desai, M.D., FAAD, discusses how managed care organizations can improve access to advanced vitiligo treatments through ...
ICER to Assess Sanofi’s Tolebrutinib for Secondary Progressive MS ...
ICER to Assess Sanofi’s Tolebrutinib for Secondary Progressive MS ...
New ACTG Trial Aims to Control HIV Without the use of ART ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback